Want to join the conversation?
Marc Goodman of UBS probes on Proair & Flonase & about the reason why Proair cannot be launched in 2016. $PRGO CEO John Hendrickson said the new products could still hit in the year, but they are not planned. Flonase is in the company's plan. Proair launch was planned at the end of CY16, but are moving out of the year seeing the dynamics.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.